Brian Daniel Webster Sells 7,857 Shares of Kestra Medical Technologies (NASDAQ:KMTS) Stock

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) insider Brian Daniel Webster sold 7,857 shares of the firm’s stock in a transaction dated Thursday, July 30th. The stock was sold at an average price of $22.72, for a total value of $178,511.04. Following the completion of the sale, the insider directly owned 549,080 shares in the company, valued at $12,475,097.60. The trade was a 1.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Daniel Webster also recently made the following trade(s):

• On Monday, August 3rd, Brian Daniel Webster sold 13,017 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $23.92, for a total value of $311,366.64.
• On Friday, July 31st, Brian Daniel Webster sold 8,948 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.60, for a total value of $202,224.80.
• On Monday, June 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $20.81, for a total value of $312,150.00.
• On Friday, May 15th, Brian Daniel Webster sold 15,000 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $20.96, for a total value of $314,400.00.

Kestra Medical Technologies Stock Performance

NASDAQ:KMTS opened at $25.93 on Wednesday. The company has a quick ratio of 4.41, a current ratio of 4.41 and a debt-to-equity ratio of 0.16. Kestra Medical Technologies, Ltd. has a twelve month low of $14.10 and a twelve month high of $30.00. The stock has a market cap of $1.52 billion, a P/E ratio of -10.71 and a beta of 0.58. The firm’s fifty day simple moving average is $22.70 and its 200 day simple moving average is $22.51.

Kestra Medical Technologies (NASDAQ:KMTS) last posted its earnings results on Tuesday, July 14th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.08). The company had revenue of $28.64 million during the quarter. Kestra Medical Technologies had a negative return on equity of 57.38% and a negative net margin of 138.35%. As a group, research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on KMTS shares. Wall Street Zen lowered Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. BTIG Research boosted their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. The Goldman Sachs Group lowered their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a research report on Thursday, April 9th. Finally, Weiss Ratings cut shares of Kestra Medical Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 16th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $27.83.

More Kestra Medical Technologies News

Here are the key news stories impacting Kestra Medical Technologies this week:

• Positive Sentiment: Analyst sentiment remains mixed but includes three Buy ratings, with a consensus price target of $27.83. BTIG Research raised its target to $32 and maintained a Buy rating, while Wolfe Research set a $30 objective. Kestra Medical Technologies insider-selling report
• Positive Sentiment: Several institutional investors increased their positions, including Russell Investments Group, Brown Brothers Harriman, Rhumbline Advisers and New Jersey’s Police & Firemen’s Retirement System. These additions provide some support for institutional interest in KMTS.
• Neutral Sentiment: Executives and insiders sold roughly 103,000 shares worth more than $2.2 million between July 30 and August 3. Sellers included CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran. Because the filings specify tax-related sales, the transactions may reflect equity vesting rather than discretionary selling.
• Negative Sentiment: The number of sellers, including the CFO, could still weigh on investor sentiment and raise concerns about management ownership. Kestra’s latest quarterly loss of $0.67 per share exceeded the expected loss of $0.59, while revenue was $28.64 million and the company remains unprofitable.

Institutional Trading of Kestra Medical Technologies

A number of large investors have recently made changes to their positions in the stock. Seven Grand Managers LLC purchased a new position in shares of Kestra Medical Technologies during the fourth quarter valued at approximately $2,652,000. Eventide Asset Management LLC boosted its holdings in Kestra Medical Technologies by 5.4% in the fourth quarter. Eventide Asset Management LLC now owns 1,269,651 shares of the company’s stock worth $33,671,000 after purchasing an additional 65,288 shares during the last quarter. Summit Partners Public Asset Management LLC bought a new stake in Kestra Medical Technologies in the 4th quarter worth approximately $9,282,000. Jennison Associates LLC grew its position in Kestra Medical Technologies by 15.0% in the 4th quarter. Jennison Associates LLC now owns 219,355 shares of the company’s stock worth $5,817,000 after purchasing an additional 28,573 shares during the period. Finally, UBS Group AG raised its stake in Kestra Medical Technologies by 34.9% during the 4th quarter. UBS Group AG now owns 270,058 shares of the company’s stock valued at $7,162,000 after buying an additional 69,908 shares during the last quarter.

Kestra Medical Technologies Company Profile

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.